Jpmorgan Chase & CO Oric Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 33,736 shares of ORIC stock, worth $259,092. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,736
Previous 35,251
4.3%
Holding current value
$259,092
Previous $361,000
24.65%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ORIC
# of Institutions
132Shares Held
67.3MCall Options Held
404KPut Options Held
6.4K-
Nextech Invest Ag5.29MShares$40.6 Million7.95% of portfolio
-
Black Rock Inc. New York, NY4.83MShares$37.1 Million0.0% of portfolio
-
Viking Global Investors LP4.43MShares$34 Million0.12% of portfolio
-
Vr Adviser, LLC New York, NY4.39MShares$33.7 Million5.85% of portfolio
-
Alkeon Capital Management LLC New York, NY3.9MShares$30 Million0.07% of portfolio
About Oric Pharmaceuticals, Inc.
- Ticker ORIC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,576,700
- Market Cap $304M
- Description
- ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...